玉溪打胎哪家医院最好玉溪哪家医院人流最安全,玉溪市做人流的好医院,玉溪哪个医院的无痛人流号,玉溪哪里做人流更安全,玉溪哪家妇科人流医院好,玉溪无痛人流哪里专业,玉溪那家医院人流做的好

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

SAN FRANCISCO, July 14 (Xinhua) -- Microsoft on Thursday introduces a hacking alert system to its Windows Live Hotmail email service alongside banning common passwords."When someone's account gets hijacked, their friends often find out before they do, because the hijacker uses their account to send spam or phishing email to all their contacts," said Microsoft in a blog post.The new security feature adds a "My friend's been hacked!" option in the "mark as" menu in Hotmail and also enables users to report hacked accounts via the junk mail filing screen.Then an alert will be sent to Microsoft, which will "make sure the account can no longer be used by spammers and activates an account recovery process to allow the owner to take back control the accounts."Users can report any email account as compromised and Hotmail will provide the information to other email providers like Yahoo! and Gmail, said the blog.Meanwhile, Microsoft said Hotmail will roll out a feature to prevent users from choosing commonly used and weak passwords, such as "123456," "ilovecats" and "gogiants." Users who currently use a weak password will be asked to change to a stronger one in the future.Hotmail, first launched in July 1996, is one of the first free email providers, and was acquired by Microsoft in 1997 for an estimated 400 million U.S. dollars.According to statistics released by comScore last August, Hotmail was then the world's largest web-based email service with around 364 million users, followed by Yahoo! Mail (280 million) and Gmail (191 million).

SYDNEY, Aug. 25 (Xinhua) -- Scientists in Australia have discovered a way of stopping mosquitoes carrying dengue virus, raising hopes for preventing the 50 million human cases of the disease every year, local media reported on Thursday.Groundbreaking experiments in Queensland have found a common insect bacteria, wMel Wolbachia, which can dramatically reduce the presence of dengue fever in mosquitoes.The research, led by Professor Scott O'Neill, Dean at Melbourne's Monash University, was published on Thursday in the prestigious journal, Nature.Australian researchers working on the Eliminate Dengue program aim to protect the mosquitoes themselves from dengue and so stop them transmitting the virus to humans."What the experiments have shown is that this strain of Wolbachia when it is put into mosquitoes really reduces the ability of the (dengue) virus to grow in the mosquito and if it can't grow, then it can't get transmitted in people," O'Neill told reporters.O'Neill said while it was too early to say if the experiments heralded the end of dengue fever, it was a major step towards that goal.In the past decade, there have been 2400 cases of dengue fever reported during 36 outbreaks in Australia.Dengue fever has become endemic in tropical regions, where it is spread by a specific type of mosquito that becomes infected after biting humans with the disease.Despite millions of people being infected with dengue each year, there is currently no way of stopping its rapid spread either by vaccines or controlling mosquito populations.Further trials will be conducted in Cairns in north Queensland over the coming wet season and approval is currently being sought for trials in Thailand, Vietnam, Brazil and Indonesia that will directly determine the effectiveness of the method in reducing dengue disease in human populations, according to Monash University.

SYDNEY, July 15 (Xinhua) -- The world's first drug to increase life expectancy of people with advanced melanoma has been approved for use in Australia, local media reported on Friday.The breakthrough drug Yervoy got approval from the Therapeutics Good Association (TGA) on Friday amid hopes it could add two years to the life of people with the most lethal form of skin cancer but for whom other treatments have failed, the Australian Associated Press (AAP) said.Clearance for the drug's use in Australia follows similar approvals by the U.S. health regulator in March.Yervoy works by attacking and destroying cancer cells.Patients are hooked up to an intravenous drip once every three weeks for a total of four doses.Professor Peter Hersey, consultant immunologist to the Melanoma Institute Australia, said no other drug had improved survival rates like Yervoy."Not all patients respond to it but those who do have a good chance of living longer than they would have otherwise," Hersey told AAP.While it may improve survival rates, Yervoy can produce side effects from diarrhea and vomiting to serious blood infections and kidney failure.The average survival time for people with advanced melanoma is just six months.A global study of 676 people with melanoma found that 45 percent of patients given Yervoy were still alive after one year, according to AAP.More than 20 percent lived at least two years, with a small number managing to survive for six years.A separate study, published in June, which showed similarly improved survival rates for patients with newly diagnosed advanced melanoma, has raised hopes that Yervoy could be made more widely available.Melanoma is the fourth most common cancer in Australia, with 10, 300 people diagnosed each year.

TOKYO, Sept. 23 (Xinhua) -- Japan's H-2A rocket carrying a new information gathering satellite was launched at the Tanegashima Space Center in Kagoshima Prefecture on Friday, local media reported.Japan has already introduced three information-gathering satellites in the wake of a missile launch by Democratic People's Republic of Korea, and the latest one will replace the No. 2 satellite which has passed its use-by date, Kydo News said.Japan's H-2A rocket lifts off from the launchiung pad at the Tanegashima space centre in Kagoshima prefecture, Japan's southern island of Kyushu on September 23, 2011. Japan launched a new spy satellite into orbit September 23, officials saidThe development cost of the fourth satellite has reached 35.9 billion yen and its launch expenses have come to 10.4 billion yen, according to the government.The Japan Aerospace Exploration Agency and Mitsubishi Heavy Industries Ltd. were forced to put off the launch three times during the past four weeks due to the approach of a powerful typhoon and discovery of a system glitch. The rocket was initially scheduled to be sent into orbit on Aug. 28.